For your patients with newly diagnosed GBM,
Optune Gio delivers the power of TTFields to attack GBM cells where they’re vulnerable1
A standard of care proven to provide long-term quality survival without adding systemic toxicity2-5,*
*Patient-reported data collected per EORTC QLQ-C30 at baseline and months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).3,6
GBM, glioblastoma; TTFields, Tumor Treating Fields.
Discover the innovation of Optune Gio
Optune Gio is a wearable treatment delivery system that can provide continuous anticancer therapy2,†
†Continuous treatment requires patient to be wearing the powered device.
Optune Gio leverages biophysical properties of the cancer cells disrupting tumor viability
Explore how it delivers TTFields, which exert antitumor effects by disrupting the activity of cancer cells during multiple phases of mitosis2
In newly diagnosed GBM,
Survival with Optune Gio + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years2,4
More time on Optune Gio resulted in a significantly greater survival benefit9,‡
‡From a post hoc analysis.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers include alternating electric fields (Optune Gio) as a Category 1 Preferred regimen, following maximal safe resection if feasible (or else biopsy), and standard radiation therapy with concurrent and adjuvant TMZ, for patients aged ≤70 years with newly diagnosed supratentorial GBM and good performance status regardless of MGMT promoter status.9,§
Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.9
§The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial on which the IFU, Instructions for Use; is based used an eligibility criteria of KPS ≥70.2,9
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Referenced with permission from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.4.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
Submit a prescription, and we take care of the rest
Personalized support from day one, from device training to reimbursement assistance and more
Optune Gio can benefit many patient types
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; KPS, Karnofsky Performance Score; MGMT, O-6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide.
References: 1. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-3295. 2. Optune Gio. Instructions For Use. Novocure; 2023. 3. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields and health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. Supplementary online content. JAMA. 2018;4(4):495-504. Accessed November 14, 2022. https://jamanetwork.com/journals/jamaoncology/fullarticle/2670704 4. Novocure Data on File US-DOF-0035. 5. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 6. EORTC Quality of Life Group. EORTC QLQ-C30, Version 3.0. 1995. European Organisation for Research and Treatment of Cancer, Belgium. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf 7. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 8. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.4.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN org.